Hippo pathway effector Yap is an ovarian cancer oncogene

Cancer Research

Volumn 70, Issue 21, 2010, Pages 8517-8525

  Hall, Chad A ^a   Wang, Runsheng ^a   Miao, Jiangyong ^b   Oliva, Esther ^b   Shen, Xiaoyun ^a   Wheeler, Thomas ^a   Hilsenbeck, Susan G ^a   Orsulic, Sandra ^b,c   Goode, Scott ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; YAP PROTEIN; YKI PROTEIN;

ADULT; AGED; ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CANCER TISSUE; CELL IMMORTALIZATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURFACE; CONTROLLED STUDY; CYTOPLASM; DISEASE COURSE; DRUG SENSITIVITY; EPITHELIAL OVARIAN CANCER; EPITHELIUM CELL; FEMALE; FLY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; NONHUMAN; ONCOGENE; OVARY CANCER; OVARY FOLLICLE CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL NUCLEUS; CELL PROLIFERATION; CISPLATIN; CYTOPLASM; DROSOPHILA MELANOGASTER; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; ONCOGENES; OVARIAN NEOPLASMS; PHOSPHORYLATION; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TRANSCRIPTION FACTORS; YOUNG ADULT;

EID: 78449290378     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-1242     Document Type: Article

References (26)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Bast RC, Jr., Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 2009;9: 415-28.
3. Cannistra SA. Cancer of the ovary. N Engl J Med 2004;351:2519-29.
4. Sale S, Orsulic S. Models of ovarian cancer metastasis: murine models. Drug Discov Today Dis Models 2006;3:149-54.
5. Goode S, Perrimon N. Inhibition of patterned cell shape change and cell invasion by Discs large during Drosophila oogenesis. Genes Dev 1997;11:2532-44.
6. Brumby AM, Richardson HE. Using Drosophila melanogaster to map human cancer pathways. Nat Rev Cancer 2005;5:626-39.
7. Zhao M, Szafranski P, Hall CA, Goode S. Basolateral junctions utilize warts signaling to control epithelial-mesenchymal transition and proliferation crucial for migration and invasion of Drosophila ovarian epithelial cells. Genetics 2008;178:1947-71.
8. Zhao B, Li L, Lei Q, Guan KL. The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev 2010;24: 862-74.
9. Sudol M. Yes-associated protein (YAP65) is a proline-rich phosphoprotein that binds to the SH3 domain of the Yes proto-oncogene product. Oncogene 1994;9:2145-52.
10. Zender L, Spector MS, Xue W, et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 2006;125:1253-67.
11. Xu MZ, Yao TJ, Lee NP, et al. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer 2009; 115:4576-85.
12. Dong J, Feldmann G, Huang J, et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 2007;130: 1120-33.
13. Miao J, Mu D, Ergel B, et al. Hepsin colocalizes with desmosomes and induces progression of ovarian cancer in a mouse model. Int J Cancer 2008;123:2041-7.
14. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998;11:155-68.
15. Auersperg N, Siemens CH, Myrdal SE. Human ovarian surface epithelium in primary culture. In Vitro 1984;20:743-55.
16. Zhao B, Wei X, Li W, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 2007;21:2747-61.
17. Steinhardt AA, Gayyed MF, Klein AP, et al. Expression of Yesassociated protein in common solid tumors. Hum Pathol 2008;39: 1582-9.
18. Zhang J, Ji JY, Yu M, et al. YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway. Nat Cell Biol 2009;11:1444-50.
19. Riedl SJ, Salvesen GS. The apoptosome: signalling platform of cell death. Nat Rev Mol Cell Biol 2007;8:405-13.
20. Overholtzer M, Zhang J, Smolen GA, et al. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci U S A 2006;103:12405-10.
21. Yuan M, Tomlinson V, Lara R, et al. Yes-associated protein (YAP) functions as a tumor suppressor in breast. Cell Death Differ 2008; 15:1752-9.
22. Mackay HJ, Oza AM. Other new targets. Int J Gynecol Cancer 2009; 19 Suppl 2:S49-54.
23. de Graeff P, Crijns AP, de Jong S, et al. Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a metaanalysis. Br J Cancer 2009;101:149-59.
24. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 2001;22:255-88.
25. Wu X, Tanwar PS, Raftery LA. Drosophila follicle cells: morphogenesis in an eggshell. Semin Cell Dev Biol 2008;19:271-82.
26. Szafranski P, Goode S. A Fasciclin 2 morphogenetic switch organizes epithelial cell cluster polarity and motility. Development 2004; 131:2023-36.